J. Montserrat (Barcelona, Spain), S. Andreas (Immenhausen, Germany)
Effects of CPAP and valsartan randomly assigned on baroreflex function and aldosterone in hypertensive OSAS
R. Tamisier, D. Lacedonia, D. Monneret, J. P. Baguet, P. Levy, J. L. Pepin (La Tronche, Grenoble Cedex 09, France)
|   |
Sleep Apnea cardioVascular Endpoints (SAVE) trial
D. McEvoy, N. Antic, E. Heeley, Y. Huang, S. Huang, J. Wang, B. Chen, Q. He, N. Zhong, C. Anderson (Adelaide, Sydney, Australia; Shanghai, , Beijing, Tianjin, China)
| |
Increased obstructive sleep apnoea (OSA) severity is associated with increased cardiovascular risk, calculated using the RISKSCORE algorithm, and reduced left ventricular function in minimally symptomatic patients
S. Craig, M. Kohler, P. Leeson, R. Davies, J. Stradling (Oxford, United Kingdom; , Switzerland)
| |
Visceral adiposity, TNFα, CRP and CPAP effect in patients with sleep apnea – A double-blind, randomized, placebo-controlled trial
P. Lee, C. W. Yu, M. T. Lin, T. T. F. Shih, H. D. Wu, W. Y. Shau, C. T. Tang, S. H. J. Hsu, P. C. Yang, C. J. Yu (Taipei, Taiwan)
| |
Relationship between sleep-disordered breathing and markers of systemic inflammation in 400 women from the general population
E. Lindberg, M. Svensson, P. Venge, C. Janson (Uppsala, Sweden)
| |
"OSA Score" as a multi-component system for predicting cardiovascular outcomes in obstructive sleep apnoea
J. M. Marin, M. Forner, E. Forcen, S. Carrizo, F. Barbe (Zaragoza, Lleida, Spain)
| |
Obstructive sleep apnoea and incident hypertension. The Zaragoza cohort study
J. M. Marin, M. Forner, A. Boldova, V. Moya, M. A. Barcelo, F. Barbe (Zaragoza, Palma de Mallorca, Lleida, Spain)
| |
Why do autoCPAP devices increase pressure during sleep in a normal subject
D. Rodenstein, B. Mwenge, M. Dury, P. Delguste (Brussels, Belgium)
| |